EGFR and non-small cell lung carcinoma: However, the secondary EGFR mutation T790M detected in NSCLC patients, can induce clinical resistance to gefitinib or erlotinib, greatly limiting the efficacy of these drugs in clinical use (Pao et al., 2005; Kosaka et al., 2006).